MLTX DEADLINE REMINDER: Berger Montague Reminds MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Important Class Action Lawsuit Deadline

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

PHILADELPHIA, Nov. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period").

Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .

MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland.

According to the lawsuit, MoonLake and certain executives made false and misleading statements regarding the Company's only drug candidate, sonelokimab (SLK), in testing as a treatment for certain skin conditions. The complaint alleges that the Company repeatedly promoted SLK's Nanobody structure as providing superior clinical advantages over traditional monoclonal antibodies, such as FDA-approved BIMZELX.

On September 28, 2025, the Company announced Phase 3 clinical trial results for SLK, which, according to the lawsuit, showed that SLK failed to achieve efficacy comparable to BIMZELX. Analysts reportedly described the data as a "disastrous result," and MoonLake's stock declined nearly 90%, or $55.75 per share, in a single trading session.

If you are a MoonLake investor and would like to learn more about this action, CLICK HERE  or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague

Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:

Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
cadorni@bergermontague.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mltx-deadline-reminder-berger-montague-reminds-moonlake-immunotherapeutics-nasdaq-mltx-investors-of-important-class-action-lawsuit-deadline-302616984.html

SOURCE Berger Montague